Individuals 12 years of age or older with a diagnosis of plaque psoriasis for at least 6 months, may qualify to participate. Eligible participants must have plaque psoriasis covering 2-20% of their body, not including scalp, palms or soles of the feet, with mild to moderate disease at the time of study entry.
Participants will receive investigational topical medication (active drug) or a placebo. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses may be provided, along with an optional open label extension upon completion of the trial.
Study participation will last 8 weeks.
Email Tina Craig, Clinical Research Coordinator at DermEffects to register.